Paxlovid Covid Treatments for the Army

Pfizer Inc., New York, was awarded a $4,852,867,500 modification (P00004) to contract W58P05-22-C-0001 for the oral therapeutic PAXLOVID. Work will be performed in New York, with an estimated completion date of March 31, 2023. Fiscal 2022 American Rescue Plan Act funds; Coronavirus Aid, Relief, and Economic Security Act funds; Coronavirus Preparedness Response and Relief Supplemental Appropriations Act funds; and Coronavirus Response and Relief Supplemental Appropriations Act funds in the amount of $4,852,867,500 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity.